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Abstract
HIV-associated sensory peripheral neuropathy (HIV-SN) afflicts approximately 50% of
patients on antiretroviral therapy, and is associated with significant neuropathic pain. Sim-
ple accurate diagnostic instruments are required for clinical research and daily practice in
both high- and low-resource setting. A 4-item clinical tool (CHANT: Clinical HIV-associated
Neuropathy Tool) assessing symptoms (pain and numbness) and signs (ankle reflexes and
vibration sense) was developed by selecting and combining the most accurate measurands
from a deep phenotyping study of HIV positive people (Pain In Neuropathy Study–HIV-
PINS). CHANT was alpha-tested in silico against the HIV-PINS dataset and then clinically
validated and field-tested in HIV-positive cohorts in London, UK and Johannesburg, South
Africa. The Utah Early Neuropathy Score (UENS) was used as the reference standard in
both settings. In a second step, neuropathic pain in the presence of HIV-SN was assessed
using the Douleur Neuropathique en 4 Questions (DN4)-interview and a body map. CHANT
achieved high accuracy on alpha-testing with sensitivity and specificity of 82% and 90%,
respectively. In 30 patients in London, CHANT diagnosed 43.3% (13/30) HIV-SN (66.7%
with neuropathic pain); sensitivity = 100%, specificity = 85%, and likelihood ratio = 6.7 ver-
sus UENS, internal consistency = 0.88 (Cronbach alpha), average item-total correlation =
0.73 (Spearman’s Rho), and inter-tester concordance > 0.93 (Spearman’s Rho). In 50
patients in Johannesburg, CHANT diagnosed 66% (33/50) HIV-SN (78.8% neuropathic
pain); sensitivity = 74.4%, specificity = 85.7%, and likelihood ratio = 5.29 versus UENS. A
positive CHANT score markedly increased of pre- to post-test clinical certainty of HIV-SN
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from 43% to 83% in London, and from 66% to 92% in Johannesburg. In conclusion, a com-
bination of four easily and quickly assessed clinical items can be used to accurately diag-
nose HIV-SN. DN4-interview used in the context of bilateral feet pain can be used to
identify those with neuropathic pain.
Introduction
HIV-associated sensory peripheral neuropathy (HIV-SN) is a length-dependent distal symmet-
rical polyneuropathy that occurs in individuals with treated and untreated HIV infection.
Increasing age and greater height appear to be universal risk factors for the neuropathy[1],
while modifiable risk factors include: advanced AIDS and lower CD4 count in untreated infec-
tion, and exposure to stavudine-basedART[2–6], and perhaps protease inhibitors[2,7,8] in
individuals receiving antiretroviral treatment (ART). However, even as less neurotoxic antire-
troviral treatment regimens are introduced globally, the prevalence of the neuropathy is not
expected to decrease appreciably[9–11].
The lack of a gold standard for accurately diagnosingHIV-SN makes proper prevalence
assessment and diseasemanagement to be challenging16. Several groups have assessed the
prevalence of HIV-SN, defined by the presence of both compatible neuropathic symptoms and
signs. A recent study in a resource-limited setting in India found 40% prevalence of HIV-SN
among untreated HIV-infected patients[12]. Studies from Africa report similar prevalence of
HIV-SN, with 37% of treatment-naïve patients[13], and ~60% of treated patients having the
neuropathy[13–15]. Moreover, the neuropathy commonly is painful. A study in South Africa
reported over 70% of patients with HIV-SN had moderate-to-severe pain and paraesthesiae
[14]. The pain fromHIV-SN has a detrimental effect on quality of life[9,16–21] and adherence
to ART[22].
Treating the pain, and treating it appropriately[23], requires identification of the pain as
being neuropathic in origin[24,25]. To provide a definite diagnosis of neuropathic pain
requires the use of specialized tests that assess large nerve fibers (quantitative sensory testing
(QST)[26–28], nerve conduction studies (NCS)), and small nerve fibers (skin biopsy for ana-
lyzing intraepidermal nerve fiber density (IENFD)[29,30], QST). Assessments such as QST and
IENFD require high levels of expertise, take a long time to perform, and are expensive, and
therefore they are not routinely available, even in well-resourced settings. And, NCS, which is
more widely available, cannot be used alone to exclude the presence of a neuropathy because
HIV-SN predominantly affects small sensory fibers, and NCS assesses large fiber function only
[29,31,32]. Thus, the diagnosis of painful HIV-SN typically relies solely on the outcome of a
clinical history and/or examination. However, performing a comprehensive neurological
examination requires time and specialist-level training to execute properly. Both these
resources are typically unavailable in busy HIV clinics, which are staffed by primary care physi-
cians, infectious diseases specialists, and nurses.
Neuropathy and neuropathic pain screening tools provide a possible solution. They provide
an abbreviated, focused assessment that can be applied and interpreted quickly by non-experts
after no or limited training[33]. Only two instruments, the Single-QuestionNeuropathy Screen
(SQNS)[34], and the Brief Peripheral Neuropathy Screen (BPNS)[35], have been developed
specifically for the assessment of HIV-SN. The SQNS only assesses symptoms and is thus sim-
ple and very quick to administer, but the trade-off is that it only yields a diagnostic certainty of
possible neuropathic pain[34]. The BPNS is more robust than the SQNS and involves the
Clinical HIV-Associated Neuropathy Tool (CHANT)
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bilateral assessment of clinical signs (ankle reflexes and vibration sense) and symptoms in the
distal limbs[35]. While the focused clinical assessment in the BPNS means that it takes more
time and some training to complete compared with the SQNS, the combination of clinical
signs and symptoms yields a diagnostic certainty of probable neuropathic pain; the minimum
level of certainty that indicates that the presence of the condition has been identified[24]. The
utility of the BPNS was assessed by comparing the QST and IENFD results of HIV-infected
individuals diagnosed as having or not having SN according to the BPNS. Unfortunately,
although the sensitivity and specificity of individual items on the BPNS were assessed against
the QST and IENFD data, validation of the BPNS scoring system, and the overall diagnostic
sensitivity and specificity of the tool was not reported[35].Moreover, in its original format, one
of the items of this instrument, the ankle reflex, involved grading the reflex, which could be dif-
ficult for non-neurologists to assess accurately[35].
For the aforementioned reasons, there is an urgent need to develop simpler, economical,
and robust clinical-based assessment tool requiringminimal training and expertise to deliver,
and which has been validated against a gold standard diagnostic comprising of both clinical
(i.e. symptoms and physical findings) and biological (i.e. epidermal innervation quantification)
criteria rendering it to have a high diagnostic accuracy close to the ideal diagnosticmethods.
This clinical-baseddiagnostic tool will not only allow analgesic therapy to be appropriately
directed, but will also be important in obtaining accurate diagnostic data for epidemiological
and neuropathy risk factor studies, including large-scale genetic studies. Furthermore, such
tool will be invaluable in ascertaining inclusion criteria for randomized controlled trials of suit-
able analgesics for neuropathic pain in both high- and low-resource settings, and assessing neu-
rotoxicity profile of antiretroviral drugs. Developing, validating, and field-testing this tool was
the objective underpinning our study describedherein.
Methods
Ethics statement
Ethical clearance for the validation study conducted in London, UK: External Peer Review,
application for UK National Health ServiceResearch Ethical Committee (NHS REC) approval
(REC Reference 13/NS/0090), NHS Research and Development (NHS R&DNumber C&W13/
058) approval, and National Institute for Health Research (NIHR Integrated Research Applica-
tion System IRAS Ref: 127698. Study ID: 15040) Portfolio Adoption was sought and full
approval was obtained. All participants provided written informed consent.
Ethical clearance for the field-test study in Johannesburg, South Africa was obtained from
the Human Ethics Research Committee (Medical), University of theWitwatersrand (clearance
number:M121018, issued: 12 July 2013). All participants provided written informed consent.
Participants were compensated for their transport costs.
Clinical Study Phases in Sequence (Fig 1A)
The development of the screening tool involved two phases:
Phase I: Development and Alpha-testing in-silico
• Development: Identification of clinical measurands from the Pain in Neuropathy Study–HIV
(HIV-PINS)[20], a comprehensive phenotyping study of HIV-SN, that were judged as poten-
tially useful and appropriate for routine clinical assessment of HIV-SN.
Clinical HIV-Associated Neuropathy Tool (CHANT)
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Fig 1. Development of the CHANT tool. (A) A summary flowchart describing important elements of our study phases in sequence. (B)
Sensitivity and specificity of newly developed CHANT tool employing all possible cutoff combinations was conducted. The four-item CHANT
was tested in silico within the stringent HIV-PINS diagnostic criteria so as to assess its accuracy performance for diagnosing neuropathy;
this testing showed a high sensitivity and specificity of 82% and 90% respectively, while employing ‘bilateral feet pain/reduced great toe
vibration’ AND ‘bilateral feet numbness/reduced ankle reflex’. Hence, this cutoff was selected to diagnose HIV-SN when applying CHANT
(Table 1). All measures were from bilateral feet.
doi:10.1371/journal.pone.0164994.g001
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• Alpha-testing in-silico: The newly developed instrument, named the ClinicalHIV-associated
Neuropathy Tool (CHANT), was tested in silico within the HIV-PINS dataset to assess its
diagnostic accuracy.
Phase II: Validation
• Internal validation: Internal validation and field-testing of CHANT was conducted in 30
HIV-infected patients (outside the HIV-PINS study) at the Kobler Clinic, St. Stephen’s Cen-
tre, Chelsea andWestminster Hospital NHS Foundation Trust, London, UK.
• External validation and field-testing: External validation and field-testing was conducted in
50 HIV-positive patients attending an outpatient clinic at Chris Hani Baragwanath Academic
Hospital, Johannesburg, South Africa.
Phase I: Development and alpha-testing of Clinical HIV-associated
Neuropathy Tool (CHANT)
Methods of Phase I. The development phase followed the triage of: i) assessing for the
presence of peripheral neuropathy, and ii) assessing whether pain co-occurringwith a neuropa-
thy was primarily neuropathic in origin (NeP), iii) assessing severity and characteristics of pres-
ent feet pain, and iv) assessing impact of present feet pain (Table 1). To assess the first triage
stage, we looked to identify elements from the HIV-PINS dataset (Pain in Neuropathy Study–
HIV[20]) that offer the best accuracy for identifyingHIV-SN. The HIV-PINS dataset includes
comprehensive sensory and psychological phenotyping data of 66 HIV-positive patients attend-
ing the Kobler Clinic, St. Stephen’s Centre, Chelsea andWestminster Hospital, London. The
cohort consisted of patients with no evidence of neuropathy and patients with neuropathy (with
and without neuropathic pain, NeP). The prevalence of neuropathy and neuropathic pain among
the HIV-PINS cohort were compatible with the epidemiological data16. The HIV-PINS case
Table 1. Description of the characters of the four selected measurand components of the neuropathy tool.
AUC on ROC analysis
(Area Under Curve on
Receiver Operator
Characteristic
analysis)
Sensitivity and
Specificity on cut-
off Crossover trade-
off between
maximally high
sensitivity and
specificity
Partial Eta-squared value
The variability in the
dependent variable
(presence or absence of
neuropathy) can be
explained or accounted
for by the independent
variable (e.g. feet pain);
variables with higher
values of partial Eta-
squared carry more
weight in defining
neuropathy.
Geometric mean cut-off
valueComputed as
geometric mean of the four
different methods of
selecting cut-off i.e.
specificity/sensitivity
crossover positive and
negative predictive value
crossover positive and
negative likelihood ratio
crossover minimal cost of
misdiagnosis
Cost of
misdiagnosisApplying a
false positive to false
negative ratio of 0.50
Feet Pain 0.79 69% 0.32 (Presence or
Absence of painful feet)
 5.5 [interpreted as mild to
moderate on pain scale of
0–10]
Cost = 0.318
Feet
Numbness
0.80 72% 0.29 (Presence or
Absence of numb feet)
 2.55 [interpreted as mild on
0–10 scale]
Cost = 0.364
Vibration 0.78 77.2% 0.264  13.2 seconds Cost = 0.306
Ankle
reflex
0.75 71.0% 0.289 (Bilaterally Reduced/
Absent Ankle Reflex)
> 5 [interpreted to a value
between ‘normal’ and
‘hypoactive’ ankle reflex]
Cost = 0.318
doi:10.1371/journal.pone.0164994.t001
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definition for HIV-SN was made of 2 or more out of the following 3 items: clinical signs of distal
sensory neuropathy elicited using the structured neurological examination, 2 or more abnormal
QST findings using the full 13 parameters of the DFNS protocol, and intraepidermal nerve fibre
density of7.63 fibers/mmon skin sample examination, meets the requirements for identifying
definite neuropathic pain proposed by Treede and colleagues[24] and those recommended by
Devigili and colleagues[36]. The HIV-PINS phenotyping data included demographic data, clini-
cal history, information about HIV and antiretroviral status, multiple questionnaires relating to
neuropathy, pain, pain co-morbidities, and neurologic phenotype assessed using a structured
neurological examination, UENS, BPNS, TCSS, the full GermanNeuropathic Pain Network
Quantitative SensoryTesting (DFNS) QST protocol[27], and IENFD.
Components of HIV-PINS that were judged as potentially useful and neurologically appro-
priate for routine clinical assessment of HIV-associated sensory neuropathy (HIV-SN) and
NeP were extracted. Similarly, potentially essential and useful components appropriate for rou-
tine clinical assessment of HIV-SN and NeP in resource-restricted and large population study
settings were identified. This process was systematically performed based on a tactic of decon-
struction and testing accuracy performance of individual components of different tools
employed within HIV-PINS, so as to identify the most accurate measurands. Composite statis-
tical analysis included detailed ROC performance for measuring diagnostic accuracy, partial
Eta squared (η2) for computing effect size in ANCOVA (Analysis of Covariance) analysis so to
indicate the accountability weight carried by each of the measurands, specificity and sensitivity
calculations to derive the true positive and negative rates, cutoff selection using different deci-
sion level thresholds, and all families of t-tests where applicable.
Four cutoff decision thresholds were employed as crossover points between the curves of
specificity and sensitivity, positive and negative predictive values, positive and negative likeli-
hood ratios, and minimal cost of misdiagnosis; the geometric value of these four methods was
used so as to develop a robust mean cutoff with central tendency. With regards to sensitivity
and specificity, the point where the sensitivity and specificity curves cross was selected as the
optimum decision level (i.e., where the maximum number of cases are correctly diagnosed as
positive or negative). Similarly, the optimum decision level for likelihood ratios was chosen as
the point where the curves of the positive and negative likelihood ratios crossover. The cross-
over point between higher values for positive likelihood ratio and lower values for negative like-
lihood ratio offer a better diagnostic accuracy (i.e., where the maximum number of cases being
associated or not associated with having HIV-SN). Likewise, the optimum decision level for
predictive values was chosen as the point of crossover between positive (where higher values
mean better accuracy) and negative (where lower values mean better accuracy) predictive val-
ues. Misdiagnosis “cost” was taken into account as the fourth method of cutoff selection. Con-
sidering the higher cost impact of missing a false positive (FP) HIV-SN case, we applied
relative misdiagnosis costs of 1 for true positives (TP), 1 for true negatives (TN), 1 for false pos-
itives (FN), and 2 for false negatives (FN), producing an FP:FN ratio of 0.5. Values >0.5 indi-
cate increasing cost. Curve plots of TP, TN, FP and FN depending on chosen cutoff value was
prepared to provide a general visual picture of how cutoff selection influences chances of hav-
ing false tests of positives or negatives. An ideal test would have a cutoff that discriminates TP
from TN without the presence of FP and FN, i.e. at the peak of each TN evolution curve. Stati-
sitical softwares used were SigmaPlot 10.0, SPSS statistics 21, Microsoft Excel + Analyse-It
3.76, and GraphPad Prism 6.
Finally, the best components identified from the HIV-PINS dataset were refined, the ques-
tion wordings improved, and the scorings simplified to generate binary outcomes. All out-
comes of CHANT were designed to result in dichotomous scores of either present (‘0’) or
absent (‘1’) and tallied for both ‘right’ and ‘left’ feet (reflecting the symmetrical presentation of
Clinical HIV-Associated Neuropathy Tool (CHANT)
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HIV-SN) to simplify assessment and scoring. These components were combined to construct an
optimal diagnostic instrument, designed to require minimal training and expertise to deliver.
In preparation of CHANT, HIV-PINS data from three previously validated tools for diag-
nosing peripheral neuropathy, in the context of diseases other than HIV infection, were decon-
structed and explored so as to identify items and cutoff values which yielded high accuracy:
Brief Peripheral Neuropathy Screen (BPNS)[35], Utah Early Neuropathy Score (UENS)[37]
and Toronto Clinical Scoring System (TCSS)[38]. Of these three tools, the BPNS was specifi-
cally developed for use in the setting of HIV-SN while UENS and TCSS were developed for dia-
betic peripheral neuropathy35-37. Utility assessment of these three instruments was made in
order to select the most accurate among the three for diagnosis of HIV-SN and to compare out-
comes to the newly developed tool (see Phase II). The cutoff scores for these three instruments
were prepared by computing geometricmeans for crossover values of sensitivity and specific-
ity, positive and negative predictive values, positive and negative likelihood ratios, and cost of
misdiagnosis[39]; the reference standard was the HIV-PINS case definition. The case defini-
tions for HIV-SN used in these three tools is summarized in S1 Panel.
The second triage question was “pain co-occurring with a neuropathy was primarily neuro-
pathic in origin”. To address this question, we used the interview component of DouleurNeu-
ropathique en 4 Questions (DN4)[40]. DN4-Interview has been selected given its 78%
sensitivity and 81.2% specificity rate of accurately diagnosingNeP when a score of3 is
employed[40], and its validation in several languages[41,42]. Since the DN4 has not previously
been used to diagnoseNeP within the setting of HIV-SN, this study has hence assessed its
validity. Study patients were given a body chart to mark for area of pain; this helped confirm
pain of plausible neuroanatomical distribution i.e. in this case, distal symmetrical pain distribu-
tion compatible with distal symmetrical polyneuropathy.
To address the third triage question “What are the severity and characteristics of the present
pain?” the following instruments were employed: the Numeric Rating Scale (NRS)[43] to assess
feet pain severity, and the Neuropathic Pain Symptoms Inventory (NPSI)[44] to characterize
the feet pain symptoms. To address question #4 “What is the impact of pain?”, the Brief Pain
Inventory (BPI)[45] was used to assess for pain interference to activities of daily living, the
Depression Anxiety Positive Outlook Scale (DAPOS)[46] for brief assessment of psychological
comorbidity, and the Insomnia Severity Index (ISI)[47] to assess overall sleep quality.
Phase II: Validation of the developed clinical tool (CHANT)
Methods of Phase II. A validation study of CHANT was conducted using the UENS as
the reference standard. A convenience sample of 30 HIV-infected out-patients (outside the
HIV-PINS cohort) at the Kobler Clinic, St. Stephen’s Centre, Chelsea andWestminster Hospi-
tal, London, UK during August and September, 2013 was recruited. Between 5–10 participants
per measurement item is deemed adequate to validate internal consistency correlations of con-
struct validity[47], hence, a pilot sample size of 30 patients was adequate to clinically validate
the 4-item instrument CHANT. Inclusion criteria were: consenting HIV-positive patients, who
were 18 years or older, and who adequately understood verbal and written English. Individuals
with concurrent severe psychological or psychiatric disorders, and those with central nervous
lesions were excluded. The study investigator (YWW)was masked to any previous diagnosis of
neuropathy. YWW conducted test-retest reliability of CHANT using the same experiment
tools under the same conditions, in the same location repeated within the same day within a
short period of time. A second study investigator (ASCR) and physicians (HY, AJ, GJ) also
administered CHANT to each participant to allow the assessment of inter-tester concordance.
The two investigators were blinded to each other’s assessment.
Clinical HIV-Associated Neuropathy Tool (CHANT)
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The validation study was conducted following a triage in the manner explained within
‘Methods of Phase I’ part of this manuscript i.e. assessing peripheral neuropathy, and assessing
whether the present feet pain in neuropathy is from NeP, assessing severity and characteristics
of present feet pain, and assessing impact of present feet pain. Face validity, content validity
ratio, inter-tester reliability, internal consistency, predictive values, likelihood ratio, and pre- to
post-test clinical probability for HIV-SN were analyzed. Likelihood ratios were emphasized as
they appropriately summarize CHANT as a diagnostic test by combining sensitivity and speci-
ficity values. Fagan’s nomogram[48,49] was applied as it provides a practical graphic and user-
friendly illustrative representation where likelihood ratios can be utilized along with a patient’s
pre-test clinical probability of HIV-SN to estimate the post-test probability of HIV-SN. Given
its high accuracy as describedwithin Results section of Phase I, the UENS was selected as the
reference standard to validate CHANT against; precaution was taken to distribute the UENS
cutoff score symmetrically over both lower limbs, and exclude cases with high unilateral scores.
Following the positive internal validation study in London (see Results section of Phase II),
an external validation and field-testing was conducted in at Chris Hani Baragwanath Academic
Hospital, Johannesburg, South Africa, using the UENS as the reference standard similar to the
study in London. A convenience sample of 50 HIV-positive out-patients was recruited. Like
the London internal validation, the CHANT, UENS and the DN4-I (with a bodymap) were
used to assess for the presence of HIV-SN and neuropathic pain. To mimic a research setting,
participants were administered CHANT and the DN4-I (with bodymap) by a clinical
researcher (PRK) trained in the assessment of ankle reflexes and vibration sense. The tools
were administered in English, and participants were asked whether they understood the ques-
tions they were asked and the description of the tests that were going to be performed.When
participants did not understand a question an interpreter, fluent in local indigenous languages,
clarified the question before the participant answered in English or their home language. Par-
ticipants also were asked whether they would prefer to have the screening tools administered in
English or their home language. On a separate occasion, participants returned to the hospital
and underwent a neurological examination of the upper and lower limbs, which included all
items assessed by the UENS. The assessment was performed by a registrar in neurology
(DGAV), who was blind to the outcome of the assessment with CHANT. Data analysis fol-
lowed that described for the London validation study.
Face validity of CHANT was assessed after the instrument was circulated among all users
and neurology experts involved within this study. Content Validity Ratio (CVR)[50,51] of
CHANT was assessed to measure the correspondence between the four measurand items and
the symptom content of HIV-SN. This was conducted by collecting responses of the following
questions from five subject matter expert (SME) panelists which included one general practi-
tioner, two neurologists, one pain medicine specialist, and one neuroscientist. The questions
were asked to indicate one response whether each of the CHANT items is 'essential,' 'useful, but
not essential,' or 'not necessary' to the performance of CHANT. CVR was then computed as
CVR = (ne—N/2)/(N/2)[50,51] where ne = number of subject matter expert panelists indicat-
ing "essential", N = total number of panelists. This formula yields values that range from +1 to
-1; positive values indicate that at least half the panelists rated the item as essential.
Results of Phase I
S1 Fig and Table 2 shows the diagnostic sensitivity and specificity, and S2 Fig shows the effect
size of individual measurands from the HIV-PINS phenotype dataset, with the HIV-PINS case
definition used as the reference standard. Our analysis identified two subjective questions of
symptoms and two objective tests of clinical signs of neuropathy that yielded the best
Clinical HIV-Associated Neuropathy Tool (CHANT)
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compromise between diagnostic accuracy and clinical utility. The two subjective items were
‘bilateral feet pain’ (sensitivity = 74%, and specificity = 81%) and ‘bilateral feet numbness’ (sen-
sitivity = 77.8% and specificity = 63.2%) (S1 Fig, Table 2). The two objective items were ‘bilater-
ally reduced great toe vibration sense’ (sensitivity = 74% and specificity = 81%) and ‘bilaterally
reduced ankle reflex’ (sensitivity = 85.7% and specificity = 68.4%) (S1 Fig, Table 2). These four
items were used to construct the prototype four-item Clinical HIV-associated Neuropathy
Tool (CHANT, complete description of the statistical characters of these four selectedmeasur-
and components of CHANT are described in Table 2). The prototype was tested in silico within
the HIV-PINS dataset, against the HIV-PINS reference standard, to assess its accuracy for
diagnosing neuropathy. This testing showed a sensitivity and specificity of 82% and 90%
respectively, while employing ‘presence of bilateral feet pain or reduced great toe vibration’
AND ‘bilateral feet numbness or reduced ankle reflex’ (Fig 1B). Hence, this cutoff was selected
to diagnoseHIV-SN when applying CHANT (Fig 1B, Table 2). A prototype tool (CHANT—
Clinical HIV-associated Neuropathy Tool; Fig 2A, S2 Panel) was created by combining and
refining the clinical phenotypes that achieved the best compromise between sensitivity and
specificity.
Among the three existing instruments (BPNS, UENS, and TCSS), the UENS had highest
diagnostic accuracy (Fig 2A and 2B), and thus was selected as the reference standard for the
validation and field-testing of CHANT (Phase II). Curve plots of counting true positives (TP),
true negative (TN), false positives (FP) and false negatives (FN) depending on chosen cutoff
value provided an overviewof how cutoff selection influenced chances of having false tests of
Table 2. Rubric on scoring the CHANT tool. These combinations of values represent all possibilities of CHANT+ve neuropathy test results. The four-item
CHANT was tested in silico within the stringent HIV-PINS diagnostic criteria so as to assess its accuracy performance for diagnosing neuropathy; this testing
showed a high sensitivity and specificity of 82% and 90% respectively, while employing a minimum of ‘bilateral feet pain/reduced great toe vibration’ AND
‘bilateral feet numbness/reduced ankle reflex’ (Fig 4). Hence, this cutoff was selected to diagnose HIV-PN when applying CHANT.
Bilateral Feet
Pain
Bilateral Feet
Numbness
Bilateral Vibration
at Great Toe
Bilateral Ankle
Reflex
CHANT +ve i.e. ‘bilateral feet pain/reduced great toe vibration’ AND
‘bilateral feet numbness/reduced bilateral ankle reflex’ (all other scores
remain CHANT–ve)
2 2 0 0 CHANT +ve
2 2 1 0 CHANT +ve
2 2 0 1 CHANT +ve
2 2 1 1 CHANT +ve
0 2 2 0 CHANT +ve
1 2 2 0 CHANT +ve
0 2 2 1 CHANT +ve
1 2 2 1 CHANT +ve
0 0 2 2 CHANT +ve
0 1 2 2 CHANT +ve
1 0 2 2 CHANT +ve
1 1 2 2 CHANT +ve
0 2 2 2 CHANT +ve
1 2 2 2 CHANT +ve
2 0 2 2 CHANT +ve
2 1 2 2 CHANT +ve
2 2 0 2 CHANT +ve
2 2 1 2 CHANT +ve
2 2 2 0 CHANT +ve
2 2 2 1 CHANT +ve
2 2 2 2 CHANT +ve
doi:10.1371/journal.pone.0164994.t002
Clinical HIV-Associated Neuropathy Tool (CHANT)
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positives or negatives (Fig 2B); at the peak of each TN (light green curve on Fig 2B); the selected
cutoffs from these three instruments of BPNS, UENS, and TCSS (Fig 2A) correlated with the
peaks of each TN on the curves (Fig 2B).
Results of Phase II
London cohort
Complete data was collected from the recruited 30 patients. There were no missing items.
Each assessment lasted around 45 minutes. Description of patient characteristics is available in
S1 Table.
Out of the 30 patients, 13 (43%; 47% in males, 33% in females) had HIV-SN based on the
CHANT tool; this was close to the neuropathy prevalence (42.42%; 28/66) reported among
HIV-PINS patients at the same center, and using the stringent HIV-PINS reference standard
[20]. Overall face validity of CHANT instrument among peer-reviewers, study investigators,
untrained observers, and study patients was acceptable. No questions were identified as ambig-
uous or confusing. Subject matter experts rated each of the four items as being essential; con-
tent validity ratio (CVR) was 0.6 for ‘feet pain’, and 1 for the remaining 3 items, with a mean
CVR of 0.9 across all four items. Spearman’s Rho (ρ) showed strong positive correlation for
inter-tester reliability among all four components of CHANT (Fig 3C, Table 3). Internal con-
sistency of CHANT was assessed using Cronbach’s α coefficient, and revealed a strong consis-
tency of 0.88 (Fig 3C, Table 3) among its four different dichotomous components, indicating
that the components of the multi-item CHANT scale measures the same concept. Item-total
correlations showed averaged behavior of 0.73 on Spearman’s Rho (Fig 3C). Each item was
consistent with the averaged behavior of all four items with very good discrimination, provid-
ing empirical evidence that all items represented the construct in CHANT, and merited inclu-
sion (Fig 3C).
When comparing CHANT results to those from UENS, 10/30 patients had HIV-SN on
UENS compared to 13/30 on CHANT. Receiver operating characteristics of CHANT using
UENS as the reference standard revealed high accuracywith area-under-curve (AUC) of 0.99
(Fig 3D). One patient was found to have a high unilateral score on UENS, and was excluded.
No patients diagnosedwith HIV-SN using the UENS were missed by the CHANT (sensitiv-
ity = 100%), but 3 patients identified as not having HIV-SN when using UENS were classified
as having SN when using CHANT (specificity of 85%). The positive predictive value (PPV)
was 77%, negative predictive value (NPV) was 100%, and the likelihood ratio (LR) was 6.67
Fig 2. Alpha-testing of CHANT in-silico. (A) ROC comparison and optimum cutoff scores were analyzed
among the three commonly employed neuropathy tools i.e. UENS, BPNS, TCSS—using the HIV-PINS
diagnostic criteria as gold standard. Whilst all three instruments show utility for diagnosing HIV-SN, UENS
has the highest accuracy, and hence selected as gold-standard for CHANT validation study. To enable
bilateral assessment, the UENS cutoff of ‘8’ was distributed symmetrically between the right and left feet.
The diagonal line depicts a performance where the specific instrument is unable to diagnose HIV-SN cases
better than chance. (B) Evolution of counting TP (true positives), TN (true negative), FP (false positives) and
FN (false negatives) was examined depending on chosen cutoff value of BPNS, TCSS, and UENS. This
figure provides a general visual picture of how cutoff selection influences chances of having false tests of
positives or negatives. An ideal test would have a cutoff that discriminates TP from TN without the presence
of FP and FN, i.e. at the peak of each TN (light green curve). (C) Item-total correlations was analyzed among
the four items of CHANT. Item-total correlations showed averaged behavior of 0.73 on Spearman’s Rho.
Each item was consistent with the averaged behavior of all four items with very good discrimination
performance, providing empirical evidence that all items represent the construct in CHANT, and merited to
be included into the composite measurement. (D) ROC analysis of CHANT performance over UENS
revealed high accuracy with area-under-curve (AUC) of 0.9895 in London validation study and 0.75 in
Johannesburg field-testing study (E).
doi:10.1371/journal.pone.0164994.g002
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(Fig 3F and 3G). In order to interpret these diagnostic test results, a nomogram[49] was applied
(red line in Fig 3H), according to which a positive CHANT result substantially increased the
pre- to post-test clinical probability of the patient having HIV-SN from 43% to over 80% in a
London tertiary-care setting.
Nine of the 13 (69.2%) CHANT+ve neuropathy patients had bilateral feet pain on body
map (BFP+ve,), and 6 of these 9 (66.7%) had DN4-interview (DN4-I) scores3/7 (median 5,
IQR: 3.5, 6.3) (Fig 4B, S2 Table). Among these 9 patients, distribution of DN4-I symptoms are
shown on Fig 4A. Additional non-DN4 descriptors used by patients to better explain their pain
include: ‘tightness over feet and legs’, ‘feels wearing tight-fitting shoes’, and ‘cramps over feet and
legs’ (all at a similar rate of 3%). Over 80% of the patients without HIV-SN (CHANT-ve) did
not have BFP and had DN4-I<3, while 6% of the patients without HIV-SN (CHANT-ve) had
bilateral feet neuropathic pain ([BFP+ve] + [DN4-I+ve]) (Fig 4C, S2 Table). Permanent spon-
taneous feet pain (question #4 of NPSI) was present among 3 of the 9 (CHANT+ve, BFP)
(33.33%), while 6/9 (66.67%) stated to have 6–10 episodes of feet pain attacks during the previ-
ous 24 hours (question #7) (S3 Table).
Johannesburg cohort
Fifty patients were recruited. Patient characteristics are available on S1 Table. None of the par-
ticipants spoke English as a first language. A language interpreter was required in 4% of assess-
ments for the first CHANT item (‘Do you have pain in your feet?), 62% for the second CHANT
item (‘Do you have numbness in your feet?), 12% for the third CHANT item (vibration test
instructions), and 10% for the fourth CHANT item (ankle reflex test instructions) (S9 Fig).
Overall, 42% of patients stated that they would prefer the instrument to be in their home lan-
guage.When using the DN4-I, 30% of the patients required the assistance of an interpreter.
Among the DN4-I items, those patients who required interpreter were 16% for the first item
Fig 3. Validation of CHANT employing UENS as gold standard. In London CHANT validation study, no
patient diagnosed using the UENS was missed by the CHANT; this resulted in sensitivity of 100%, specificity
of 85%, PPV (positive predictive value) of 77%, NPV (negative predictive value) of 100% (A), and LR+
(positive likelihood ratio) of 6.67, and LR- (negative likelihood ratio) of 0 (B). In Johannesburg CHANT field-
testing study, CHANT had sensitivity of 74.42%, specificity of 85.71, PPV of 96.97%, NPV of 35.3% (A), LR
+ of 5.29, and LR- of 0.30 (B). Both the validation and field-testing revealed high accuracy. (C) Nomogram
was made for interpreting the CHANT validation and field-testing diagnostic test results. In both
circumstances of London (red line) and Johannesburg (blue line), a positive CHANT score has significantly
increased clinical certainty of the patient having HIV-PN i.e. 43% to 85% in London (red line), and 66% to
92% in Johannesburg (blue line).
doi:10.1371/journal.pone.0164994.g003
Table 3. London CHANT validation study: Reliability (inter-investigator), internal consistency, and item-total correlations. Spearman’s Rho
showed strong positive correlation for inter-tester reliability among all four components of the CHANT. Internal consistency of CHANT was assessed using
Cronbach’s α coefficient—and this revealed a strong consistency of 0.88 among its four different dichotomous components indicating that the multi-item
CHANT scale measures the same concept, i.e. peripheral neuropathy.
CHANT Reliability (Inter-tester) Spearman’s Rho (ρ) Item-Total correlation Spearman’s Rho (ρ)
Foot Pain (Right) 1 Bilateral Feet Pain: 0.744
Foot Pain (Left) 1 Bilateral Feet Numbness: 0.717
Foot Numbness (Right) 1 Bilateral Vibration Reduction: 0.583
Foot Numbness (Left) 1 Bilateral Ankle Reflex Reduction: 0.858
Vibration (Right) 0.933 Averaged item-total correlation: 0.7255
Vibration (Left) 0.944 -
Ankle Reflex (Right) 0.968 -
Ankle Reflex (Left) 0.985 Internal Consistency Cronbach’s α: 0.8832
doi:10.1371/journal.pone.0164994.t003
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(‘whether the pain had burning characteristics’), 16% for the second item (‘whether the pain
had painfully cold characteristics’), 26% for the third item (‘whether the pain had electric shocks
characteristics), 81% for the fourth item (‘whether the pain had association with tingling symp-
toms in the same area), 52% for the fifth item (‘whether the pain had association with pins and
needles symptoms in the same area), 77% for the sixth item (‘whether the pain had association
with numbness symptoms in the same area), and 45% for the seventh item (‘whether the pain
Fig 4. Features of HIV-SN in London and Johannesburg. (A) Frequency of symptoms from the DN4-Interview among the HIV-SN patients (CHANT+ve)
with BFP (Bilateral Feet Pain) in London Internal Validation Study (blue bars) and in Johannesburg External Validation Study (red bars) was examined.
Within the London cohort, nine of the 13 (69.23%) CHANT+ve neuropathy patients had bilateral feet pain on body map (BFP+ve), and 6 of these 9 (66.67%)
had their DN4-interview (DN4-I) score3/7 (median 5 (IQR: 3.5, 6.25)). Among these 9 patients, symptoms were described in the following decreasing
frequency: ‘electric shocks’ (56%), ‘numbness’ (56%), ‘pins and needles’ (44%), ‘burning’ (44%), ‘tingling’ (33%), ‘itching’ (22%), and ‘painful cold (11%).
Additional descriptors used by patients to better explain their pain include: ‘tightness over feet and legs’, ‘feels wearing tight-fitting shoes’, and ‘cramps over
feet and legs’. Among the Johannesburg cohort (red bars), more than half of all the patients had all of the DN4-I symptom items, while ‘pins and needles’ was
found to be most frequently present among 90% of the patients. (B) Distribution of symptoms of Bilateral Feet Pain (BFP), and DN4-I was evaluated among
patients found to have HIV-SN as per the CHANT instrument in London Internal Validation Study (blue bars) and in Johannesburg External Validation Study
(red bars). Among the London cohort (blue bars), close to 70% of these patients with HIV-SN had BFP and associated neuropathic pain ([BFP+ve] + [DN4-I
+ve])–demonstrating the higher capacity of CHANT to identify BFP and associated neuropathic pain. Thirty % of those with HIV-SN (CHANT+ve) did not
have BFP. Among the Johannesburg cohort (red bars), over 75% of these patients with HIV-SN had BFP and associated neuropathic pain ([BFP+ve] +
[DN4-I+ve])–demonstrating the higher capacity of CHANT to identify BFP and associated neuropathic pain. Eighteen % of those with HIV-SN (CHANT+ve)
did not have BFP. (C) Distribution of symptoms of Bilateral Feet Pain (BFP), and DN4-I was assessed among patients found not to have HIV-SN as per the
CHANT instrument in London validation study (blue bars) and Johannesburg validation study (red bars). Over 80% of the London cohort patients without
HIV-SN (blue bars) did not have BFP and had DN4-I-ve, while only 6% of these patients without HIV-SN were found to have associated bilateral feet
neuropathic pain ([BFP+ve] + [DN4-I+ve]). Nearly 90% of the Johannesburg cohorts without HIV-SN (red bars) neither had BFP nor associated neuropathic
pain ([BFP+ve] + [DN4-I+ve])–demonstrating the higher capacity of CHANT to identify BFP and associated neuropathic pain in this setting; only around 10%
of those without HIV-SN (CHANT-ve) were found to have BFP and DN4-I+ve. (D) Comparison of HIV-SN, HIV-SN with bilateral feet pain (BFP), and HIV-SN
associated bilateral feet neuropathic pain (NeP) was made between London and Johannesburg CHANT studies. In general, these results showed that there
was moderately higher magnitude of both HIV-SN and HIV-SN associated neuropathic pain within the Johannesburg setting as compared to the setting in
London; there was correlation evident between the three trends i.e. an increase in any of the three at one setting correlates to an increase in the other
setting.
doi:10.1371/journal.pone.0164994.g004
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had association with itchy symptoms in the same area). Overall, 48% of the patients stated that
they would prefer the instrument to be translated in their home language.
There was a 66% (33/50) prevalence of HIV-SN based on CHANT, out of which 26
(78.79%) had bilateral feet NeP on (DN4-I+ve, BFP on CHANT). Five of the eight males
(62.5%) and 28/ 42 (66.7%) females were CHANT+ve. All 5/5 (100%) CHANT+ve males and
21/28 (75%) CHANT+ve females had NeP (DN4-I+ve, BFP). Clinical characteristics of partici-
pants with and without neuropathy on the CHANT tool are shown in S3–S8 Figs. When using
the UENS, 43/50 (86%) had HIV-SN. Using the UENS as the reference standard, CHANT had
a ROCAUC of 0.75 (Fig 3E), sensitivity of 74.42%, specificity of 85.71, PPV of 96.97%, NPV of
35.3%, and a LR of 5.29. A positive CHANT score markedly increased clinical certainty of the
patient having HIV-SN from 66% (pre-test probability) to 92% (post-test probability) (Fig 3H).
Of those patients with HIV-SN (CHANT+ve), 82% (n/N) had BFP; 93% (n/N) of those with
BFP had associated neuropathic pain (DN4-I scores 3/7; BFP+ve + DN4-I+ve; Fig 4E).
Among the HIV-SN patients who had BFP, DN4-I symptoms were described in the following
decreasing frequency: ‘pins and needles’ (89%), ‘burning’ (85%), ‘numbness’ (85%), ‘tingling’
(74%), ‘electric shocks’ (63%), ‘itching’ (63%) and ‘painful cold (59%) (Fig 4A). Additional non-
DN4 descriptors used by patients to better explain their pain included ‘cramps over feet and
legs’. Over 75% of the patients with HIV-SN (CHANT+ve) had bilateral feet neuropathic pain
([BFP+ve] + [DN4-I+ve]) (Fig 4B). Eighteen percent of those with HIV-SN (CHANT+ve) did
not have BFP (Fig 4B). Nearly 90% of the patients without HIV-SN neither had BFP nor associ-
ated neuropathic pain ([BFP+ve] + [DN4-I+ve]). Only ~10% of thosewithout HIV-SN
(CHANT-ve) had BFP and DN4-I+ve (Fig 4C).
Discussion
We undertook to develop and validate a screening tool for assessing HIV-SN that has high accu-
racy and clinical utility. CHANT was developed by combining four high-performing and easily
assessed clinical measurands from the deep phenotyping HIV-PINS dataset. CHANT achieved
high accuracy on alpha-testing with sensitivity and specificity of 82% and 90%, respectively. In 30
patients in London, CHANT diagnosed 43.3% (13/30) HIV-SN (66.7%with neuropathic pain);
sensitivity = 100%, specificity = 85%, and likelihood ratio = 6.7 versus UENS, internal consis-
tency = 0.88 (Cronbach alpha), average item-total correlation = 0.73 (Spearman’s Rho), high
test-retest reliability = 0.85, and inter-tester concordance> 0.93 (Spearman’s Rho). In 50 patients
in Johannesburg, CHANT diagnosed 66% (33/50) HIV-SN (78.8% neuropathic pain); sensitiv-
ity = 74.4%, specificity = 85.7%, and likelihood ratio = 5.29 versus UENS. A positive CHANT
score markedly increased of pre- to post-test clinical certainty of HIV-SN from 43% to 83% in
London, and from 66% to 92% in Johannesburg. DN4-interviewused in the context of bilateral
feet pain can be used to identify those with neuropathic pain.
The development of CHANT met the methodologicalquality criteria describedby COSMIN
(Consensus-based Standards for the selection of healthMeasurement Instruments)[52] for
design requirements of clinical measurement properties (S3 Panel). However, developing
screening tools for neuropathy and neuropathic pain is limited by the lack of gold standard
diagnostic criteria. This means that the measures of validity and reliability we report for
CHANT may over-estimate the true performance of the instrument. To minimize this error in
Phase I of the tools development, we used a strict definition of neuropathy as our reference
standard i.e. the HIV-PINS case definition for HIV-SN. In Phase II we did not have the
required phenotype information to use this stringent case definition as the reference standard,
and had to use a proxy measure, the UENS. The UENS was developed using a reference stan-
dard based on a case definition of similar stringency to that used for HIV-PINS[37]. The
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diagnostic properties of the UENS were confirmed in our study when we assessed it in our
HIV-PINS cohort (Fig 3A). Nevertheless, the UENS is not 100% sensitive or specific, and thus
we accept that the validity measures we report in Phase II are likely to be slightly inflated com-
pared to if we had used a more stringent reference standard.
If the UENS performedwell during Phase I, why do we not just use the UENS for assessing
HIV-SN? Firstly, the UENS was not constructed to specifically address the symmetrical charac-
teristics of HIV-SN, and therefore there is the potential for false positives for HIV-SN arising
in unwary users as a result of high-scoring unilateral peripheral nerve lesion (e.g. radiculopa-
thies). The CHANT was designed to overcome this limitation by keeping neuropathy symme-
try central to its diagnostic criteria. Secondly, unlike CHANT, the UENS exclusively uses
neurological examination items. The incorporation of signs and symptoms into the diagnostic
definition of CHANT means that it is more closely aligned to the neuropathic pain grading sys-
tem proposed by Treede and colleagues[24]. And lastly, while both tools include ankle reflexes
and vibration sense, the UENS includes relative grading of both these items (normal, dimin-
ished, absent), whereas the CHANT records only presence and absence of the signs. This sim-
plificationmay reduce the sensitivity of CHANT compared to the UENS, but it makes
CHANT more readily usable by non-neurologists; one of our key aims. We acknowledge our
limitation of not conducting test-retest reliability within the CHANT validation; we aim to
include test-retest evaluations in the future.
The BPNS is the most frequently used screening tool for assessment of HIV-SN in the
research setting, but the instrument’s overall sensitivity and specificitywere never adequately
described[35].Nevertheless, there is strong convergence between the BPNS, whose develop-
ment relied on clinical insight, and CHANT. Both assess the bilateral presence of two clinical
signs (ankle reflexes and vibration sense) and symptoms (CHANT: pain and numbness; BPNS:
pain, numbness, paresthesia). The most commonly used case definition of BPNS requires at
least one bilateral sign and one bilateral symptom, while the case definition for CHANT can be
made by based on the bilateral presence of two symptoms (pain and numbness) even if there
are no signs present (Fig 2A).
Bilateral feet pain (BFP) was present among 69.23% of the neuropathy cases.While validat-
ing DN4-interview combining with bodymap pain distribution, it was found that 2/3rd of
these neuropathy patients with BFP were classified as having bilateral neuropathic foot pain
(NeP), which compares to similar previous values found on applying more stringent and
sophisticated criteria. HIV-SN is primarily a diffuse, non-focal PN; these features makes pain
characteristics to be aberrant, and hence necessitates bodymap for identifying pain distribu-
tion along with DN4-Interview cutoff, or apply the DN4-Interview specific to pain on bilateral
feet. The DN4-Interviewwas originally developed for focal NeP diagnosis, nonetheless our
results showed its successful validation for HIV-SN NeP diagnosis. The three neuropathy cases
with BFP but with no NeP need to be classified as Pain of Probably Neuropathic Origin
(POPNO) until further confirmatory follow-up tests. It was interesting to note that foot pain
was not a presenting feature among 4 of the 13 (30.77%) neuropathy cases. This supports the
inclusion of ‘foot numbness’ and the two neurological examinations while constructing the
CHANT tool. There was only one patient (3.33%) with no neuropathy where only BFP was
present; he was referred for closer follow up as he may have presented with subclinical neurop-
athy. Three of the six patients (50%) with bilateral feet NeP had permanently persisting sponta-
neous pain, i.e. a classic feature of severity and chronicity in NeP. Two of the six (33.33%) NeP
patients had dynamic mechanic allodynia over both feet.
Overall analysis of severity, characteristics, and impact of pain revealed a trend of progres-
sive increment from no-neuropathy, to neuropathy, and to NeP. Application of bodymap was
helpful in identifying pain specific to distal peripheral feet. NeP measurement instruments
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should employ descriptors mentioned by patients themselves e.g. ‘tightness over feet and legs’,
‘as if wearing tight-fitting shoes’, ‘cramps over feet and legs’. NeP largely impacted lifestyles, par-
ticularly of sleep disturbance and pain interference with daily activities. The DAPOS scale was
not discriminatory for psychological comorbidities between the no-neuropathy and neuropa-
thy/NeP cases. This necessitates the design of a proper instrument that measures psychological
comorbidities specific to patients with bilateral feet NeP, since concomitant presence of other
somatic symptoms can influence outcomes. E-health resources can be used to develop smart-
phone application of the CHANT instrument for handy use among health professionals to
help aid rapid diagnosis and triage.
We conducted validation and field-testing at two locations, London and Johannesburg. The
selection of these cohorts allowed us to assess CHANT in a group of native English speakers
and a group whose first language was not English. CHANT performedwell in both cohorts,
although some aspects of CHANT (especially the question on numbness) and the DN4-I (espe-
cially tingling and numbness) required the use of an interpreter in the Johannesburg cohort.
That CHANT had higher sensitivity and NPV in London validation compared to equivalent
specificity and higher PPV in Johannesburg validation implies that CHANT can be utilized to
rule out HIV-SN in the former, and rule inHIV-SN in the latter. This result fits to the charac-
teristics of the two different settings in London and Johannesburg of our studies i.e. confirma-
tory tests are more available within the former setting compared to the later. Interpreting test
results requires insight into the population for which the test is designed. Applying diagnostic
or screening tests in low-prevalence settings can be misleading due to false positive results. One
strategy to further improve the PPV of CHANT is to shift from screening everyone (universal
screening) to screening selectively, e.g. testing only people with high risk (e.g. taller and older
patients, patients on known neurotoxic drugs, or symptoms that suggest HIV-SN). A highly-
sensitive test such as CHANT within London setting will identify most cases of HIV-SN, so a
CHANT-ve test reassures that the patient is least likely to have HIV-SN. Lower prevalence of
HIV-SN in Londonmeans that a negative CHANT result is more accurate within that setting;
higher HIV-SN prevalence in Johannesburg means that a positive CHANT result is more accu-
rate within that setting. Application of tests to enhance the diagnostic likelihood leads to the
notion of likelihood ratios. In both circumstances of London and Johannesburg, a positive
CHANT score has markedly increased clinical certainty of the patient having HIV-SN i.e. 43%
to 85% in London, and 66% to 92% in Johannesburg (Fig 3H). Negative CHANT test in Lon-
don would definitely rule out HIV-SN, while a negative test in JHB will require re-evaluation
follow-up if symptoms continue. A positive CHANT result gives higher clinical certainty of
HIV-SN in Johannesburg. The HIV-SN patients with bilateral feet pain (BFP) in Johannesburg
describedmore pain symptoms compared to those in London; this indicates that the clinical
utility of this combination of CHANT, BFP, and DN4-I can be further enhanced as it helps to
rule out HIV-SN associated bilateral feet neuropathic pain in Johannesburg (i.e. with a negative
test result), while it can be used to rule inHIV-SN associated bilateral feet neuropathic pain in
London (i.e. with a positive test result). In summary, all these results support the development
of CHANT as an appropriate and accurate tool for diagnosingHIV-SN in large population and
low resource clinical settings.
Comparison of Results from London and Johannesburg
Comparison between the accuracy performance of CHANT within London and Johannesburg
cohorts shows higher sensitivity in London and higher specificity in Johannesburg) (Fig 3F).
Comparison of HIV-SN, HIV-SN with bilateral feet pain (BFP), and HIV-SN associated bilat-
eral feet neuropathic pain (NeP) between London and Johannesburg CHANT studies revealed
Clinical HIV-Associated Neuropathy Tool (CHANT)
PLOS ONE | DOI:10.1371/journal.pone.0164994 October 20, 2016 17 / 23
that there was moderately higher magnitude of both HIV-SN and HIV-SN associated neuro-
pathic pain within the Johannesburg setting as compared to the setting in London; there was
correlation evident between the three trends i.e. an increase in any of the three at one setting
correlates to an increase in the other setting (Fig 4D). Comparison of frequency of DN4-I
symptom items among the HIV-SN patients (CHANT+ve) with BFP (Bilateral Feet Pain) in
London and Johannesburg Validation Studies showed that the patients in the Johannesburg
cohort describedmore pain symptoms compared to those in London. Comparison of bilateral
feet pain (BFP) and DN4-I scores between the patients in London and Johannesburg revealed
slightly more number of patients with BFP and associated neuropathic pain (BFP+, DN4-I+)
among the Johannesburg cohort; however the tool’s capacity to identify these patients was
comparable in both settings (Fig 4D). The higher risk for pretest probability of having HIV-SN
in African settings can make CHANT yield a high positive predictive value (PPV); this is
because PPV results rely on pretest prevalence. In addition, differences in exposure to poten-
tially neurotoxic antiretrovirals in Johannesburg and Londonmay have influenced results.
Conclusion
We found that combination of four clinical items is sufficient to accurately diagnoseHIV-SN.
CHANT provides a valid, reliable, practical, measurable, sensitive tool requiringminimal train-
ing and expertise to deliver for clinical research and daily practice. Assessment of inherent psy-
chometric properties of CHANT demonstrated adequate performance. DN4-Interview along
with bodymap is a valid tool to diagnose neuropathic pain among those with HIV-SN.
Supporting Information
S1 Fig. Sensitivity and specificity analysis of measurand items employedwithin the HIV--
PINS (Pain in Neuropathy Study–HIV) dataset.The triumvirate HIV-PINS diagnostic crite-
ria of clinical findings, QST (Quantitative SensoryTesting) abnormalities, and IENFD
(Intraepidermal Nerve Fiber Density) results were used as gold-standard. Clinical items with
high sensitivity and specificity i.e. feet numbness, feet pain, reduction in ankle reflex and great
toe vibration were selected to construct CHANT (Clinical HIV-associated Neuropathy Tool).
As shown herewith, these four clinical items performed accurately compared to most of the
demanding neuropathy investigations. All items represent measures from bilateral feet.
(TIF)
S2 Fig. Partial Eta-squared values of measurand items employedwithin the HIV-PINS
(Pain in Neuropathy Study–HIV) dataset.The four clinical items with high sensitivity and
specificity i.e. feet numbness, feet pain, reduction in ankle reflex and great toe vibration that
were selected to construct CHANT (Clinical HIV-associated Neuropathy Tool) also carried
higher accountability effect size compared to most of the demanding neuropathy investiga-
tions. All items represent measures from bilateral feet.
(TIF)
S3 Fig. Age of participants stratified by diagnosis. In both cohorts of Johannesburg and Lon-
don, there was no statistically significant increase in age (years) from no-neuropathy
(CHANT-ve), to neuropathy (CHANT +ve), and to neuropathic pain (CHANT+ve, BFP+ve,
DN4-I+ve) (Kruskal-Wallis followed by Dunn’s post-hoc analysis).
(TIF)
S4 Fig. BMI (BodyMass Index) of participants stratified by diagnosis. In both cohorts of
Johannesburg and London, there was no statistically significant difference in BMI among cases
with no-neuropathy (CHANT-ve), neuropathy (CHANT +ve), and neuropathic pain
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(CHANT+ve, BFP+ve, DN4-I+ve) (Kruskal-Wallis followed by Dunn’s post-hoc analysis).
(TIF)
S5 Fig. Height of participants stratified by diagnosis. In both cohorts of Johannesburg and
London, there was no statistically significant difference in height among cases with no-neurop-
athy (CHANT-ve), neuropathy (CHANT +ve), and neuropathic pain (CHANT+ve, BFP+ve,
DN4-I+ve) (Kruskal-Wallis followed by Dunn’s post-hoc analysis).
(TIF)
S6 Fig. Waist:Hip ratio of participants stratified by gender and diagnosis.Among females,
CHANT+ve neuropathy and neuropathic pain (NeP) (CHANT+ve, BFP+ve, DN4-I+ve) cases
had no statistically significant difference inW:H ratio compared to CHANT-ve. Among males,
there was no statistically significant difference inW:H ratio betweenCHANT+ve neuropathy,
NeP cases, and CHANT-ve, (Kruskal-Wallis inter-median difference, post-test Dunn).
(TIF)
S7 Fig. Female:Male (F:M) ratio stratified by diagnosis. F:M ratio was up to 13 times higher
in Johannesburg compared to London. F:M ratio was comparable among those with no neu-
ropathy (CHANT-ve), neuropathy (CHANT+ve), and neuropathic pain (CHANT+ve, BFP
+ve, DN4-I+ve).
(TIF)
S8 Fig. NRS (Numerical Rating Scale),DAPOS (Depression, Anxiety, and Positive Outlook
Scale),BPI (Brief Pain Inventory), and ISI (Insomnia Severity Index) scores in London
cohort.NRS, DAPOS, BPI, and ISI showed observable progressively increasing trend from no-
neuropathy (CHANT-ve), neuropathy (CHANT+ve), neuropathy with bilateral feet pain
(CHANT+ve, BFP+ve), and neuropathic pain (CHANT+ve, BFP+ve, DN4-I+ve). Inter-
median BPI (Brief Pain Inventory) difference was statistically significant (p< 0.05, Kruskal-
Wallis followed by Dunn’s post-hoc analysis) between no-neuropathy CHANT-ve cases and
neuropathy CHANT+ve cases; among neuropathy CHANT+ve cases, there was no statistically
significant inter-median BPI difference (Kruskal-Wallis followed by Dunn’s post-hoc analysis)
between (CHANT+ve, BFP) and (CHANT+ve, BFP, DN4-I+ve).
(TIF)
S9 Fig. Frequency of Interpreter Requirement among the study patients in Phase-III
(Johannesburg).More than half of the patients required interpreters for the items of ‘tingling’,
‘numbness’, and ‘pins and needles’; this reminds the importance of devising tools that have bet-
ter comprehensibility for their enhanced utility in field settings where English is a second- or
third-language.
(TIF)
S1 Panel. Case definition for HIV-SN used by BPNS, UENS, and TCSS.
(PDF)
S2 Panel. Instruction on how to performCHANT.
(PDF)
S3 Panel. Standards Checklist for the CHANT Prototype (COSMIN).
(PDF)
S1 Table. LondonCHANT validation study: Inter-median comparison of age, height, and
other sociodemographicvariables.
(PDF)
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S2 Table. Comparison of DN4-I (Interviewpart of DouleurNeuropathique 4 Questions)
scores among all, no neuropathy (CHANT-), neuropathy (CHANT+), neuropathy with
bilateral feet pain (CHANT+, BFP+), and neuropathic pain (CHANT+, BFP+, DN4-I+)
patients in London cohort Phase II CHANT internal validation study. There was statisti-
cally significant difference between those with neuropathic pain and no neuropathic pain,
between neuropathy and no neuropathy, between neuropathy and all, and between neuro-
pathic pain and all (Dunn’s multiple comparison test, p< 0.05).
(PDF)
S3 Table. LondonCHANT validation study. Outcomes of NPSI to describe the 9 (CHANT
+ve, BFP) patients who showed varied characteristics and severity on all 12 questions. Perma-
nent spontaneous feet pain (question #4 of NPSI) was present among 3 of the 9 (33.33%), while
6/9 (66.67%) stated to have 6–10 episodes of feet pain attacks during the previous 24 hours
(question #7).
(PDF)
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